Jasper announces final results from Phase 1 study of briquilimab

Jasper Therapeutics announced that positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia, AML, in complete remission or myelodysplastic syndromes, MDS, undergoing allogeneic hematopoietic cell transplant, HCT, will be presented during an oral session at the America Society of Hematology, ASH, 2023 Annual Meeting & Exposition, being held December 9-12, 2023, in San Diego, CA. The study being presented demonstrated that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the associated short and long-term toxicities that accompany busulfan-based regimens commonly used in transplant of donor or gene-corrected cells. “We are pleased to be able to present positive final results from this study in an oral presentation at the ASH Annual Meeting, which support a favorable safety profile for briquilimab as well as its clinical potential in a variety of indications and patient types,” said Edwin Tucker, M.D., Chief Medical Officer of Jasper. “While we have more recently prioritized our development efforts in addressing mast cell diseases, we continue to enroll a Phase 1 trial evaluating briquilimab as a second-line therapy in subjects with LR-MDS and look forward to presenting data from that study next year.”